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microRNAs are single-stranded, non-coding RNAs that regulate gene expression. The microRNA-16 family has been reported to 
be involved in cell-cycle regulation, which could also downregulate expression of multiple pro-proliferation genes. The present 
results demonstrated that miR-16 expression in HeLa cells increased when the cells were arrested during S-phase under methyl 
methanesulfate (MMS) treatment. This further resulted in downregulation of a target protein CDC25A, whereas miR-16 expres-
sion did not increase when HeLa cells were arrested during the MMS-treated G0/G1 or G2/M phase. Furthermore, when HeLa cells 
were arrested during S-phase with hydroxyurea treatment, miR-16 expression did not increase. These results suggest that expres-
sion levels of microRNAs in mammalian cells are delicately regulated under variable cellular conditions. 
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microRNAs (miRNAs) are single-stranded, non-coding 
RNAs, ~21 to 23-nucleotides in length, which are generated 
from larger precursors transcribed from non-coding genes 
[1]. Results show that miRNAs, as gene regulatory mole-
cules, are involved in many physiological and pathological 
processes, such as proliferation, differentiation, and    
tumorigenesis [2]. In addition, the function of miRNAs in 
mammalian cells has been shown to predominantly decrease 
target mRNA levels [3]. Furthermore, miRNAs could have 
a tuning role in regulating gene expression; and the unique 
features of miRNA-mediated gene regulation have recently 
been characterized, including the rapid turning off of pro-
tein production, as well as reversibly and compartmental-
ized regulating gene expression [4]. These properties could 
allow miRNAs to rapidly respond to subtle environmental 
changes or intracellular stresses. 
The miRNA-16 (miR-16) family is involved in cell-cycle 
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regulation, which down-regulates expression of multiple pro- 
proliferation factors, such as CDK6 and Cyclin D1, result-
ing in G0/G1 arrest [5,6]. Interestingly, cell-cycle inhibition 
of miR-16 is cell-type dependent, and over-expression of 
miR-16 significantly increases G0/G1 population in 
HCT116, A549, and MCF7 cells, but does not induce a 
measurable cell-cycle change in HeLa cells [5]. In addition, 
repression of Cyclin D1 by miR-16 results in G0/G1 arrest of 
A549 cells, whereas the same effect leads to no G0/G1 ac-
cumulation in HepG2 or MEG-01 cells [6]. It is possible 
that miR-16 targets act in concert, rather than individually, 
and differential effects are due to various cellular contexts.  
The present study analyzed expressional change of 
miR-16 levels in HeLa cells at different stages of cell cycle 
with different DNA-damage reagents. Results showed that 
miR-16 expression in HeLa cells was upregulated only 
when cells were arrested in S-phase under methyl methane-
sulfate (MMS) treatment. 
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1  Materials and methods 
1.1  Materials 
Hydroxyurea (HU), methyl methanesulfate (MMS), RNase 
A and propidium iodide (PI) were purchased from Sigma- 
Aldrich. Fetal bovine serum (FBS) and DMEM medium 
were purchased from Invitrogen Life Technologies. HeLa 
cells were obtained from American Type Culture Collec-
tion. CDC25A antibody was purchased from Cell Signaling 
Technology; β-actin antibodies were purchased from Santa- 
Cruz; anti-mouse IgG, anti-rabbit IgG and ECL kit were 
purchased from Amersham. 
1.2  Cell culture and cell synchrony 
HeLa cells were cultured in Dulbecco’s-modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum (FBS) and 
100 U/mL penicillin/streptomycin (Gibco) at 37°C. For 
synchronization experiments, exponentially growing HeLa 
cells were initially treated with 2 mmol/L hydroxyurea 
(HU) for 12 h, were released in a HU-free medium for 10 h, 
and then subjected to a second round of HU treatment for 
12 h. Ultimately, highly synchronized cells were obtained at 
the G1/S boundary. For drug-treatment experiments, HeLa 
cells from the HU double-block were released and subjected 
to 0.8-mmol/L MMS treatment at the indicated time points.  
1.3  Flow cytometric analysis 
HeLa cells were harvested and fixed with 70% ethanol at 
4°C. The fixed cells were resuspended in a PBS solution 
containing 500 μg/mL RNase A and incubated at 37°C for 1 
h. Cellular DNA was stained with 30 μg/mL PI. Flow  
cytometry analysis was performed with a FACScalibur flow 
cytometer (BD FACScan). 
1.4  Western blot analysis 
HeLa cells were lysed in 1× SDS buffer (50 mmol/L Tris, 
2% SDS, 0.1% bromophenol blue, 10% glycerol, 100 
mmol/L DTT, pH 6.8) and boiled for 10 min. Whole cell 
lysates were subjected to 10% SDS-PAGE gel electropho-
resis, and the proteins were then transferred to PVDF mem-
branes using a semi-dry transfer system (Bio-Rad). After 
blocking with 10% non-fat milk in TBS-T for 1 h, the 
membrane was probed with primary monoclonal antibody 
specific to CDC25A (1:1000) for 90 min, or β-actin (1:2000) 
for 90 min, which served as an internal control. Membranes 
were further incubated with anti-mouse IgG or anti-rabbit 
IgG and detected using an ECL kit. 
1.5  RNA extraction and qRT-PCR 
Total RNA from cultured HeLa cells was extracted using 
Trizol Reagent (Invitrogen) according to manufacture pro-
tocols. Reverse transcription was performed using 200 ng 
total RNA with 0.2 μL MMLV Reverse Transcriptase (Ta-
kara) according to the manufacture protocol. qRT-PCR was 
performed as described using a real-time PCR Quantitation 
Kit (GenePharma). PCR reactions were conducted using an 
ABI3000 real-time PCR machine at 95°C for 3 min, fol-
lowed by 40 cycles of 95°C for 12 s and 62°C for 50 s. Each 
sample was analyzed in triplicate, and U6 snRNA was used 
for normalization. The abundance of miR-16 in HeLa cells, 
which was relative to the average expression, was calcu-
lated using RQ=2−ΔΔCT, where ΔΔCT=(CT miRNA−CT U6 RNA) 
experimental − (CT miRNA−CT U6 RNA) control. 
1.6  Anti-miR-16 transfection 
Equal numbers of HeLa cells (3 × 104) were seeded into 
6-well culture plates and cultured for 1 d, followed by in-
cubation with 2 mmol/L HU for 12 h. The HU-treated cells 
were then incubated with fresh medium and transiently 
transfected with synthesized anti-miR-16 oligonucleotides 
(miR-16 inhibitor) at a final concentration of 100, 200 and 
400 nmol/L using Llipofectamine 2000 reagent (Invitro-
gen), respectively, for 6 h. Synthesized random oligonu-
cleotides served as the miR-16 negative control. Following 
transfection, the transfectants were re-cultured with fresh 
medium for an additional 4 h, treated with 2 mmol/L HU for 
12 h, and subjected to further analysis. 
2  Results and discussion 
2.1  S-phase dependent miR-16 upregulation in MMS- 
treated HeLa cells  
We recently reported that cell-cycle progression of HeLa 
cells could be arrested with a DNA damaging alkylating 
agent MMS, showing that cells at different phases exhibit 
different sensitivity to MMS treatment [7]. The same ob-
servation was shown in Figure 1(c): S-phase HeLa cells 
(3-h release from HU-double block; see Materials and 
methods) were fully arrested with 0.8 mmol/L MMS treat-
ment, G2/M-phase cells (7-h release) were partially delayed, 
and G1-phase cells (12-h release) were arrested at G0/G1 
phase under the same MMS treatment. Interestingly, data 
from real-time PCR analysis revealed that MMS treatment 
significantly increased miR-16 expression in S-phase-   
arrested HeLa cells, whereas miR-16 upregulation was not 
observed in G2/M-phase and G0/G1-phase arrested HeLa 
cells under the same MMS treatment (Figure 1(d)). miR-16 
expression in different phases of untreated HeLa cells (Fig-
ure 1(a)) was also measured and served as the control, of 
which expression levels at different phases did not reveal 
significant variation (Figure 1(b)). In summary, these results 
suggest that miR-16 upregulation in MMS-treated HeLa 
cells is S-phase-dependent. 
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Figure 1  S-phase dependent upregulation of miR-16 expression in MMS-treated HeLa cells. (a) HeLa cells were synchronized at the G1/S boundary using 
the HU double-block method. Synchronized HeLa cells were released from the HU-block for 3 h and represented S-phase cells, for 7 h and represented 
G2/M-phase cells, and for 12 h and represented G1-phase cells. Cellular DNA contents were analyzed by flow cytometry. Arrowheads indicate 2N and 4N 
DNA contents. (b) miR-16 expression in exponentially growing HeLa cells and HeLa cells at different phases, as detected by qRT-PCR. U6 snRNA was 
used to normalize. Data are representative of 3 independent experiments (mean ± SD). (c) Synchronized HeLa cells were released from HU-block for the 
indicated times. Subsequently, the cells were treated with 0.8 mmol/L MMS: the 3-h-released cells (S-phase cells) were treated with MMS for 4 h, the 
7-h-released cells (G2/M-phase cells) were treated with MMS for 5 h, and the 12-h-released cells (G1-phase cells) were treated with MMS for 6 h. Cellular 
DNA contents were analyzed by flow cytometry. Arrowheads indicate 2N and 4N DNA contents. (d) miR-16 expression in HeLa cells at different phases, 
with or without MMS treatment, was detected by qRT-PCR. U6 snRNA was used to normalize. Data are representative of 3 independent experiments (mean 
± SD). Asterisk indicates P < 0.05. 
2.2  miR-16 upregulation results in decreased CDC25A 
expression 
Because CDC25A, an cell-cycle regulator in S phase [8], was 
reported to be negatively regulated by miR-16 [5,9], expres-
sion levels of CDC25A protein in S-phase HeLa cells were 
measured with or without MMS treatment by Western blot 
analysis. Results revealed significantly downregulated 
CDC25A protein in S-phase-arrested HeLa cells treated with 
MMS (Figure 2(a) and (b)), suggesting that upregulation of 
miR-16 expression in S-phase-arrested cells resulted in down-
regulated CDC25A expression. This was in agreement with a 
 
Figure 2  Up-regulation of miR-16 causes functionally decreased 
CDC25A proteins. (a) Western blot analysis of CDC25A in HeLa cells 
(lane 1, exponentially growing cells (control); lane 2, S-phase cells; lane 3, 
S-phase cells treated with 0.8 mmol/L MMS for 4 h;). β-actin was used as 
the loading control. (b) ImageJ software was used to analyze relative 
CDC25A levels from the western blot results in (a). Data are representative 
of 3 independent experiments (mean ± SD). Asterisk indicates P < 0.05. 
previous report that downregulated CDC25A transcription 
levels were solely dependent on UV-induced miR-16 in a 
miR-16 knockdown experiment (see Figure 5D of ref. [9]).  
The regulatory relationship between miR-16 and 
CDC25A was further confirmed using synthesized anti- 
miR-16 oligonucleotides (Materials and methods). Results 
showed that inhibition of miR-16 upregulation by the 
miR-16 inhibitor rescued the downregulation of CDC25A 
expression in the MMS-induced S-phase-arrested HeLa 
cells (Figure 3(a) and (b)). These results suggest that miR-16 
directly regulate CDC25A expression, which is supported by 
a previous luciferase activity experiment with a RLuc- 
CDC25A-3′UTR fragment [9]. However, recovered CDC25A 
expression in the presence of the miR-16 inhibitor did not 
release the MMS-induced inhibitory effects of S-phase pro-
gression (data not shown), implying that rescue of CDC25A 
downregulation by miR-16 alone might not be sufficient for 
recovery of MMS-induced S-phase-arrested HeLa cells. These 
results indicate that specific upregulation of miR-16 expres-
sion in MMS-treated S-phase-arrested HeLa cells could func-
tionally downregulate targets such as CDC25A.  
2.3  miR-16 expression is not upregulated in HU-in-
duced S-phase-arrested HeLa cells 
Hydroxyurea (HU) is an inhibitor of ribonucleotide reducetase 
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Figure 3  Inhibition of miR-16 upregulation rescues downregulation of 
CDC25A. (a) HeLa cells were transiently transfected with miR-16 inhibitor 
(100, 200 and 400 nmol/L) or miR-16 negative control, as described in 
Material and methods. miR-16 expression in these cells was detected by 
qRT-PCR. U6 snRNA was used to normalize. Asterisk indicates P < 0.05. 
(b) Western blot analysis of CDC25A in HeLa cells (lane 1, exponentially 
growing cells; lane 2, S-phase cells; lane 3, S-phase cells treated with 
MMS for 4 h; lane 4, S-phase cells transfected with the miR-16 negative 
control (200 nmol/L) and treated with MMS for 4 h; lanes 5–7, S-phase 
cells transfected with the miR-16 inhibitor (100, 200 and 400 nmol/L, 
respectively) and treated with MMS for 4 h. β-actin was used as the load-
ing control. 
and has been widely used for synchronizing cells at the G1/S 
point, but it also induces DNA strand breaks in mammalian 
cells [10]. Our previous work showed that longer exposure 
to HU resulted in higher levels of DNA damage in CHO 
cells, as well as S-phase arrest [11]. In the present study, 
S-phase HeLa cells were treated with indicated concentra-
tions of HU for 4 h, respectively. The HU treatments re-
sulted in arrest of HeLa cells at the S-phase (Figure 4(a)). 
However, real-time PCR analysis did not detect significant 
upregulation of miR-16 expression in HU-induced S-phase- 
arrested cells (Figure 4(b)). Furthermore, Western blot 
analysis revealed similar protein levels of CDC25A be-
tween untreated S-phase HeLa cells and HU-treated S-phase 
cells (Figure 4(c)). In conclusion, these results showed that 
MMS treatment resulted in upregulation of miR-16 expres-
sion, but HU treatment did not induce this effect, although 
both drug-treatments resulted in S-phase arrest of HeLa 
cells. 
It is widely recognized that different kinds of DNA 
damage during S-phase result in differential activation of 
various signaling pathways in the DNA damage checkpoint 
[12–14]. As a widely-used DNA damaging alkylating agent, 
MMS adds methyl groups to DNA at 7-guanine or 3-ade-
nine, thereby inducing structural damage or DNA sin-
gle-stranded breaks [15], which often activate the base exci-
sion repair pathway [16]. In contrast, HU treatment causes 
DNA double-stranded breaks in mammalian cells, as well 
replication disturbances [10–12], which induces activation 
 
Figure 4  miR-16 expression in S-phase HeLa cells treated with HU. (a) S-phase cells were treated respectively with 2, 4 and 8 mmol/L HU for 4 h, and 
subjected to flow cytometry analysis. Arrowheads indicate 2N and 4N DNA contents. (b) S-phase cells were treated with 2, 4 and 8 mmol/L HU for 4 h, 
respectively, and then miR-16 expression was detected by qRT-PCR. U6 snRNA was used to normalize. Data are representative of 3 independent experi-
ments (mean ± SD). (c) Western blot analysis of CDC25A of HeLa cells (lane 1, exponentially growing cells; lane 2, S-phase cells; lanes 3–5, S-phase cells 
treated with HU (2, 4, and 8 mmol/L, respectively) for 4 h; β-actin served as the loading control. 
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of the ATM/Chk2 pathway [17,18]. It has been reported that 
MMS activates the p21-dependent S-phase DNA damage 
checkpoint, but suppresses the CDC25A-dependent check-
point, whereas UV irradiation results in entirely opposite 
cellular responses within the same cells [19]. Based on these 
observations, it is possible that upregulation of miR-16 ex-
pression relies on a particular cellular context determined by 
MMS-induced responses in terms of the S-phase checkpoint 
selection, whereas no such cellular context is generated un-
der by HU treatment.  
In conclusion, the present study demonstrates that ex-
pression levels of miRNAs in mammalian cells are deli-
cately regulated under variable cellular contexts, which are 
determined by particular stages of the cell cycle and/or by 
different environmental stresses.  
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